Public Meeting on Nanotechnology Materials
in FDA Regulated Products
October 10, 2006 -- Natcher Auditorium, Bethesda, Maryland

9:00: Welcome - FDA Task Force Co-chairs

9:15: National/Regional Perspectives

Dr. Celia Merzbacher, U.S. Office of Science and Technology Policy

Dr. Philippe Martin, European Commission

Dr. Delara Karkan, Health Canada

10:00: Session 1: General science, policy, or use of nanotechnology materials in FDA-regulated products

John Balbus, Environmental Defense [TXT] [PowerPoint Presentation]

David Berube, International Council on Nanotechnology [presentation]

Carolyn Cairns, Consumers Union

Kenneth David, Michigan State University [TXT] [PowerPoint Presentation ]

Stacey Harper, Oregon State University [TXT] [PowerPoint Presentation]

Matthew Jaffe, US Council for International Business

11:00: Break

11:15 Session 2: General science, policy, or use of nanotechnology materials in FDA-regulated products (continued)

Martin Philbert, University of Michigan, School of Public Health [TXT] [PowerPoint Presentation]

David Rejeski, Project on Emerging Nanotechnologies [TXT] [PowerPoint Presentation]

Michael Taylor, School of Public Health, University of Maryland

Bruce Levinson, Center for Regulatory Effectiveness

Kathy Jo Wetter, ETC Group [presentation]

12:15: Lunch (on your own)

1:30: Session 3: Science, policy, or nanotechnology material use in cosmetics, personal care products, or topically applied products

Pascal Delrieu, Kobo Products Inc. [TXT] [PowerPoint Presentation]

Jane Houlihan, Environmental Working Group

George Kimbrell, International Center for Technology Assessment [TXT] [PowerPoint Presentation]

Erich Pica, Friends of the Earth

Michael Roberts, University of Queensland, School of Medicine [TXT] [Powerpoint Presentation]

Annette Santamaria, ENVIRON International Corp. [presentation]

2:30: Session 4: Science, policy, or nanotechnology material use in drugs, biologics, or devices

Phillip Buckler , Kereos, Inc. [TXT] [PowerPoint Presentation]

Neil Desai, Abraxis Bioscience Inc [TXT] [PowerPoint Presentation]

Anil Diwan, NanoViricides, Inc. [TXT] [PowerPoint Presentation]

Piotr Grodzinski, National Cancer Institute [TXT] [PowerPoint Presentation]

3:15: Break

3:30: Session 5: Science, policy, or nanotechnology material use in drugs, biologics, or devices (continued)

Deborah Ladenheim, Avidimer Therapeutics Inc [TXT] [PowerPoint Presentation]

Bernie Liebler, AdvaMed

Scott McNeil, Nanotechnology Characterization Laboratory [TXT] [PowerPoint Presentation]

4:00: Session 6: Science, policy, or nanotechnology material use in food products

Lutz End, BASF [TXT] [PowerPoint]

4:25: Presentations from on-site registrants

Igor Linkov, Intertox, Inc.

John Bailey, Cosmetic, Toiletry, and Fragrance Association

Jay Anderson, VEECO, Inc.

Sean Murdock, Nanobusiness Alliance

5:25: Closing remarks -- FDA Task Force Co-chairs

5:35: Adjourn

horizontal rule